
Shidong Jia, MD, PhD, is the founder and global CEO of Predicine, a Silicon Valley precision-oncology company building multi-omic liquid biopsy tests that read cancer from blood and urine. Trained as a physician-scientist at Harbin Medical University, Peking Union Medical College, Dana-Farber and Harvard, he ran oncology biomarker strategy at Genentech before leaving to start Predicine in 2015. His pitch is simple: precision diagnostics to enable precision medicine, built 'From Pharma, For Pharma.'

Andre Esteva, PhD, is the co-founder and CEO of ArteraAI, a medical AI company whose test for personalizing prostate cancer therapy is included in NCCN clinical guidelines, reimbursed by Medicare, and deployed internationally. A Stanford-trained AI scientist whose Nature cover paper first demonstrated that AI could match dermatologists at diagnosing skin cancer, Esteva has co-founded four companies with a combined market cap of $2.2B. Named to TIME100 Health 2025 and Modern Healthcare's 40 Under 40 for 2025, he leads a company that raised $175M total and was named a TIME 2024 Best Invention.